Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT05246995 Not yet recruiting - Solid Tumor Clinical Trials

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Start date: March 23, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 combined with Sintilimab in patients with advanced solid tumors

NCT ID: NCT05219981 Not yet recruiting - Solid Tumor Clinical Trials

18F F-AraG-PET Imaging to Evaluate Immunological Response CKI Therapy in Solid Tumors Imaging

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This is A pilot study of using [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor

NCT ID: NCT05115500 Not yet recruiting - Solid Tumor Clinical Trials

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of antibody-drug conjugate combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory solid tumors with HER-2 positive

NCT ID: NCT05109832 Not yet recruiting - Solid Tumor Clinical Trials

A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects

Start date: October 30, 2021
Phase: Phase 1
Study type: Interventional

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 Following a Single Oral Dose to China Healthy Male Subjects

NCT ID: NCT05095441 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Start date: March 15, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma (GBM).

NCT ID: NCT04866485 Not yet recruiting - Solid Tumor Clinical Trials

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Start date: June 14, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.

NCT ID: NCT04841421 Not yet recruiting - Solid Tumor Clinical Trials

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Start date: May 1, 2021
Phase: Early Phase 1
Study type: Interventional

The primary objective of this study is to observe the distribution of 89Zr-CD147 and radiation dosimetry characteristics in patients with solid tumors. The secondary objective is to observe the pharmacokinetic characteristics of 89Zr-CD147 in patients with solid tumors. This study is a single-center, open-lable study, including 89Zr-CD147 1mCi±10%,89Zr-CD147 3mCi±10% and 89Zr-CD147 5mCi±10% dose group. The trial is expected to last for 2 years from the first patient signing the consent form to the end of the trial.

NCT ID: NCT04569916 Not yet recruiting - Solid Tumor Clinical Trials

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Start date: September 2020
Phase: Phase 2
Study type: Interventional

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

NCT ID: NCT04550663 Not yet recruiting - Colorectal Cancer Clinical Trials

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

Start date: September 25, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

NCT ID: NCT04545827 Not yet recruiting - Colorectal Cancer Clinical Trials

Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours

Start date: June 2021
Phase: Phase 1
Study type: Interventional

A study to assess the safety of IMM-01 in participants with advanced solid tumors